Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

LiraglutideInterpret the evidence

What pediatric clinic records add to the liraglutide evidence

3 numbered sourcesSource years 2025, 2026

Peptides are short amino-acid chains linked by peptide bonds. Some can activate receptors that respond to hormones released after meals. Liraglutide is a modified peptide that activates the glucagon-like peptide-1, or GLP-1, receptor. In 2026, investigators examined health records to see how blood sugar measures changed in young people with type 2 diabetes who received liraglutide in a clinical setting. [1]

The study used records from 2020 through 2023. It compared changes in HbA1c, a blood test that reflects average glucose exposure over the preceding months. At 26 weeks, the liraglutide group had a larger numerical decrease in HbA1c than the control group. The difference did not reach the study’s usual threshold for statistical significance. At 52 weeks, the comparison also did not establish a difference. Body mass index scores adjusted for age and sex were stable in both groups. [1]

The authors found differences in some cholesterol measures, but those measurements were available in only a small subset of the participants. That matters for interpretation. The people whose charts contain a follow-up cholesterol test can differ from the people without one. The study’s analysis also involved different numbers of records at different time points. A missing measurement could reflect how the clinic scheduled tests or something about a patient’s course. [1]

In this study, treatment choices were made in clinical practice. The investigators then looked back at what was recorded. This provides evidence about the outcomes that can be observed in a care setting. A randomized trial can better separate the effect of treatment assignment from the characteristics of the people who received it. The two methods answer related questions using different comparisons. [1]

The U.S. Victoza label includes improving glycemic control in adults and children aged 10 years and older with type 2 diabetes, with diet and exercise. That indication is distinct from the weight-management indication for Saxenda, another liraglutide product with different eligibility. The 2026 observational analysis describes recorded glucose and cholesterol measures in young people with type 2 diabetes. Its results belong to that clinical question. [1, 2, 3]

Sources

Original works cited in this article. Links open the external record in a new tab.

Shop Liraglutide

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Also available as Markdown or JSON.